StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Consolidated Net Income by Year

Consolidated Net Income ($M)

Novartis Consolidated Net Income: $13,967M in FY2025, up 17.0% from a year earlier.

Latest, FY2025
13,967
Period ended Dec 31, 2025
Change on a year earlier
+17.0%
11,939 in FY2024
History
11 years
Since FY2015
Sources
9
Documents cited below

Where the FY2025 figure comes from

Source: Novartis 20-F (0001114448-26-000004, filed 2026-02-04) ↗

Reported in Postgres DB + Form 6-K.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Novartis Consolidated Net Income ($M), annual FY2015–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/db-is-net-inc-cons

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.